Company / Capital Expenditures
Gilead Sciences Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$563.0M
FY2025
5-year range
$523.0M / $825.0M
FY2021-FY2025
Trend
+7.6%
vs FY2024
Sector context
#9 of 194
Health Care
What the data says
Among 194 Health Care companies, Gilead Sciences is in the top 5% for capital expenditures. Capital Expenditures returned to growth in FY2025 after 3 years of decline, reaching $563M.
Based on SEC 10-K filings.
$563M in FY2025 with a 5-year CAGR of -2.8%. Top quartile in the Health Care sector.
Declined from $579M to $563M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -4.7%
- 5-Year CAGR
- -2.8%
- 10-Year CAGR
- -
Sector benchmark
Top 5% in Health CareTop 5% of 194This company $563.0M Sector average $117.5M
▼
+379.1% above sector average
Key checks
Key Insights
- 5-year CAGR of -2.8%, indicating a declining trend.
- In FY2025, capital expenditures increased 7.6% year-over-year.
- Ranks #9 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2021.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $563.0M | +7.6% |
| FY2024 | $523.0M | -9.7% |
| FY2023 | $579.0M | -10.9% |
| FY2022 | $650.0M | -21.2% |
| FY2021 | $825.0M | +26.9% |
| FY2020 | $650.0M | +10.2% |
| FY2019 | $590.0M | -21.1% |
| FY2018 | $748.0M | +0.1% |
| FY2017 | $747.0M | +34.1% |
| FY2016 | $557.0M | -25.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026